Brought to you by 
Existing investors put $26mm more into Sutro Biopharma through Series D round
16 Dec 2013
Executive Summary
Sutro Biopharma Inc. (antibody-drug conjugates and bispecific antibodies for cancer) raised $26mm through a Series D round from returning investors Alta Partners, Amgen Ventures, Celgene Corp. (partner under a 2012 deal), Lilly Ventures, Skyline Ventures, and SV Life Sciences. Proceeds will help expand the company's immuno-oncology pipeline.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Existing investors put $26mm more into Sutro Biopharma through Series D round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice